Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary

Executive summary of the Global Strategy for Prevention, Diagnosis and Management of COPD 2023: the latest evidence-based strategy document from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) https://bit.ly/3KCaTGe

[1]  A. Agustí,et al.  Exacerbations in COPD: a personalised approach to care. , 2023, The Lancet. Respiratory medicine.

[2]  Paul D. Thomas,et al.  Lifetime spirometry patterns of obstruction and restriction, and their risk factors and outcomes: a prospective cohort study. , 2022, The Lancet. Respiratory medicine.

[3]  C. McEvoy,et al.  Lifetime lung function trajectories and COPD: when the train derails. , 2022, The Lancet. Respiratory medicine.

[4]  Meilan K. Han,et al.  Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function. , 2022, The New England journal of medicine.

[5]  S. Salvi,et al.  The availability, cost, and affordability of essential medicines for asthma and COPD in low-income and middle-income countries: a systematic review , 2022, The Lancet. Global health.

[6]  Meilan K. Han,et al.  Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission , 2022, The Lancet.

[7]  D. Mannino,et al.  Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for its Revision. , 2022, American journal of respiratory and critical care medicine.

[8]  I. Pavord,et al.  Treatable traits in the NOVELTY study , 2022, Respirology.

[9]  S. Fuke,et al.  Home High-Flow Nasal Cannula Oxygen Therapy for Stable Hypercapnic COPD: A Randomized Clinical Trial , 2022, American journal of respiratory and critical care medicine.

[10]  A. Forsythe,et al.  Epidemiology, Healthcare Resource Utilization, and Mortality of Asthma and COPD in COVID-19: A Systematic Literature Review and Meta-Analyses , 2022, Journal of asthma and allergy.

[11]  E. Wan.  The Clinical Spectrum of PRISm , 2022, American journal of respiratory and critical care medicine.

[12]  A. Koczulla,et al.  Using a smartphone application maintains physical activity following pulmonary rehabilitation in patients with COPD: a randomised controlled trial , 2022, Thorax.

[13]  Yi Zhang,et al.  High-flow nasal cannula versus conventional oxygen therapy in acute COPD exacerbation with mild hypercapnia: a multicenter randomized controlled trial , 2022, Critical Care.

[14]  F. Maltais,et al.  Ambient Air Pollution and Dysanapsis: Associations with Lung Function and Chronic Obstructive Pulmonary Disease in the Canadian Cohort Obstructive Lung Disease Study , 2022, American Journal of Respiratory and Critical Care Medicine.

[15]  E. Silverman,et al.  Genetics of chronic obstructive pulmonary disease: understanding the pathobiology and heterogeneity of a complex disorder. , 2022, The Lancet. Respiratory medicine.

[16]  A. Agustí,et al.  Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene-environment interactions across the lifespan. , 2022, The Lancet. Respiratory medicine.

[17]  C. Jenkins,et al.  Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment. , 2022, The Lancet. Respiratory medicine.

[18]  K. Balakrishnan,et al.  Household air pollution and COPD: cause and effect or confounding by other aspects of poverty? , 2022, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[19]  B. Celli,et al.  Chest CT‐assessed comorbidities and all‐cause mortality risk in COPD patients in the BODE cohort , 2022, Respirology.

[20]  M. Miravitlles,et al.  Are short courses of antibiotic therapy as effective as standard courses for COPD exacerbations? A systematic review and meta-analysis. , 2022, Pulmonary pharmacology & therapeutics.

[21]  Z. Ademi,et al.  Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis , 2021, BMJ.

[22]  Meilan K. Han,et al.  Treatment Trials in Pre-COPD and Young COPD: Time to Move Forward. , 2021, American journal of respiratory and critical care medicine.

[23]  A. Sheikh,et al.  Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes , 2021, European Respiratory Journal.

[24]  C. Gregoretti,et al.  ERS clinical practice guidelines: high-flow nasal cannula in acute respiratory failure , 2021, European Respiratory Journal.

[25]  A. Agustí,et al.  Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation: A Randomized Clinical Trial. , 2021, JAMA.

[26]  J. Wedzicha,et al.  An Updated Definition and Severity Classification of COPD Exacerbations: The Rome Proposal. , 2021, American journal of respiratory and critical care medicine.

[27]  Y. Lacasse,et al.  Oximetry neither to prescribe long-term oxygen therapy nor to screen for severe hypoxaemia , 2021, ERJ Open Research.

[28]  M. Miravitlles,et al.  Reduction in hospitalised COPD exacerbations during COVID-19: A systematic review and meta-analysis , 2021, PloS one.

[29]  A. Ramírez-Venegas,et al.  The “Slow Horse Racing Effect” on Lung Function in Adult Life in Chronic Obstructive Pulmonary Disease Associated to Biomass Exposure , 2021, Frontiers in Medicine.

[30]  B. Nordestgaard,et al.  Supernormal lung function and risk of COPD: A contemporary population-based cohort study , 2021, EClinicalMedicine.

[31]  P. Ran,et al.  Pulmonary tuberculosis as a risk factor for chronic obstructive pulmonary disease: a systematic review and meta-analysis , 2021, Annals of translational medicine.

[32]  C. Tromeur,et al.  Prevalence of Pulmonary Embolism Among Patients With COPD Hospitalized With Acutely Worsening Respiratory Symptoms. , 2021, JAMA.

[33]  N. Thakur,et al.  Reassessment of Home Oxygen Prescription after Hospitalization for Chronic Obstructive Pulmonary Disease A Potential Target for Deimplementation , 2021 .

[34]  M. Sjoding,et al.  Racial Bias in Pulse Oximetry Measurement. , 2020, The New England journal of medicine.

[35]  B. Nordestgaard,et al.  Relationship between supernormal lung function and long-term risk of hospitalisations and mortality: a population-based cohort study , 2020, European Respiratory Journal.

[36]  J. Wedzicha,et al.  From GOLD 0 to Pre-COPD , 2020, American journal of respiratory and critical care medicine.

[37]  Sally J. Singh,et al.  Predictors of Referral to Pulmonary Rehabilitation from UK Primary Care , 2020, International journal of chronic obstructive pulmonary disease.

[38]  F. Martinez,et al.  Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease , 2020, American journal of respiratory and critical care medicine.

[39]  B. Nordestgaard,et al.  Importance of Early COPD In Young Adults for Development of Clinical COPD: Findings from the Copenhagen General Population Study. , 2020, American journal of respiratory and critical care medicine.

[40]  G. Washko,et al.  Phenotypic characterisation of early COPD: a prospective case–control study , 2020, ERJ Open Research.

[41]  M. Montes de Oca.  Smoking Cessation/Vaccinations. , 2020, Clinics in chest medicine.

[42]  M. Miravitlles,et al.  Prevalence of α1-antitrypsin PiZZ genotypes in patients with COPD in Europe: a systematic review , 2020, European Respiratory Review.

[43]  P. Dorinsky,et al.  Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. , 2020, The New England journal of medicine.

[44]  Benjamin M. Smith,et al.  Association of Dysanapsis With Chronic Obstructive Pulmonary Disease Among Older Adults. , 2020, JAMA.

[45]  L. Kinsman,et al.  Risk factors for all-cause hospital readmission following exacerbation of COPD: a systematic review and meta-analysis , 2020, European Respiratory Review.

[46]  M. Steiner,et al.  Pulmonary rehabilitation at a time of social distancing: prime time for tele-rehabilitation? , 2020, Thorax.

[47]  R. Stockley.  Alpha-1 Antitrypsin Deficiency: The Learning Goes On , 2020, American journal of respiratory and critical care medicine.

[48]  Meilan K. Han,et al.  Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in COPD Patients. , 2020, American journal of respiratory and critical care medicine.

[49]  Harry J de Koning,et al.  Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. , 2020, The New England journal of medicine.

[50]  A. Agustí,et al.  BRONCHIAL INFECTION AND temporal evolution OF bronchiectasis in patients with chronic obstructive pulmonary disease. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[51]  G. Tikellis,et al.  Home-based or remote exercise testing in chronic respiratory disease, during the COVID-19 pandemic and beyond: A rapid review , 2020, medRxiv.

[52]  E. Kerwin,et al.  Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial , 2019, Respiratory Research.

[53]  J. Hogg,et al.  Update on the Pathogenesis of Chronic Obstructive Pulmonary Disease. , 2019, The New England journal of medicine.

[54]  Meilan K. Han,et al.  Noninvasive Imaging Biomarker Identifies Small Airway Damage in Severe Chronic Obstructive Pulmonary Disease , 2019, American Journal of Respiratory and Critical Care Medicine.

[55]  P. Cullinan,et al.  The occupations at increased risk of COPD: analysis of lifetime job-histories in the population-based UK Biobank Cohort , 2019, European Respiratory Journal.

[56]  David Couper,et al.  Discriminative Accuracy of FEV1:FVC Thresholds for COPD-Related Hospitalization and Mortality. , 2019, JAMA.

[57]  A. Agustí,et al.  Lung function trajectories in health and disease. , 2019, The Lancet. Respiratory medicine.

[58]  N. Seersholm,et al.  COPD exacerbations: the impact of long versus short courses of oral corticosteroids on mortality and pneumonia: nationwide data on 67 000 patients with COPD followed for 12 months , 2019, BMJ Open Respiratory Research.

[59]  M. Weatherall,et al.  Oxygen versus air-driven nebulisers for exacerbations of chronic obstructive pulmonary disease: a randomised controlled trial , 2018, BMC Pulmonary Medicine.

[60]  B. Make,et al.  Women manifest more severe COPD symptoms across the life course , 2018, International journal of chronic obstructive pulmonary disease.

[61]  I. Farver-Vestergaard,et al.  Lower mortality after early supervised pulmonary rehabilitation following COPD-exacerbations: a systematic review and meta-analysis , 2018, BMC Pulmonary Medicine.

[62]  K. Rabe,et al.  Inhaled corticosteroids in COPD: friend or foe? , 2018, European Respiratory Journal.

[63]  J. Wedzicha,et al.  At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease , 2018, American journal of respiratory and critical care medicine.

[64]  J. Alison,et al.  Telerehabilitation for chronic respiratory disease , 2018, Cochrane Database of Systematic Reviews.

[65]  Meilan K. Han,et al.  Anemia and Adverse Outcomes in a Chronic Obstructive Pulmonary Disease Population with a High Burden of Comorbidities. An Analysis from SPIROMICS , 2018, Annals of the American Thoracic Society.

[66]  Meilan K. Han,et al.  Once‐Daily Single‐Inhaler Triple versus Dual Therapy in Patients with COPD , 2018, The New England journal of medicine.

[67]  N. Roche,et al.  Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial , 2018, The Lancet.

[68]  Cui Guo,et al.  Effect of long-term exposure to fine particulate matter on lung function decline and risk of chronic obstructive pulmonary disease in Taiwan: a longitudinal, cohort study. , 2018, The Lancet. Planetary health.

[69]  N. Meda,et al.  Chronic obstructive pulmonary disease associated with biomass fuel use in women: a systematic review and meta-analysis , 2018, BMJ Open Respiratory Research.

[70]  J. Bigna,et al.  Prevalence of chronic obstructive pulmonary disease in the global population with HIV: a systematic review and meta-analysis. , 2017, The Lancet. Global health.

[71]  M. Mirzaee,et al.  Prevalence and predictors associated with severe pulmonary hypertension in COPD , 2017, The American journal of emergency medicine.

[72]  E. Wouters,et al.  Cognitive impairment and clinical characteristics in patients with chronic obstructive pulmonary disease , 2017, Chronic respiratory disease.

[73]  J. Brugada,et al.  Lung function in early adulthood and health in later life: a transgenerational cohort analysis. , 2017, The Lancet. Respiratory medicine.

[74]  J. Wedzicha,et al.  Combined Impact of Smoking and Early‐Life Exposures on Adult Lung Function Trajectories , 2017, American journal of respiratory and critical care medicine.

[75]  B. Beghé,et al.  Chronic respiratory abnormalities in the multi-morbid frail elderly , 2017 .

[76]  Y. Li,et al.  Tiotropium in Early‐Stage Chronic Obstructive Pulmonary Disease , 2017, The New England journal of medicine.

[77]  G. A. Whitmore,et al.  Diagnostic Instability and Reversals of Chronic Obstructive Pulmonary Disease Diagnosis in Individuals with Mild to Moderate Airflow Obstruction , 2017, American journal of respiratory and critical care medicine.

[78]  Joanna Picot,et al.  Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. , 2017, The Cochrane database of systematic reviews.

[79]  F. Martinez,et al.  Effect of roflumilast in patients with severe COPD and a history of hospitalisation , 2017, European Respiratory Journal.

[80]  Claus Vogelmeier,et al.  Global Initiative for Chronic Obstructive Lung Disease (GOLD) 20th Anniversary: a brief history of time , 2017, European Respiratory Journal.

[81]  R. Suruki,et al.  Stability of Blood Eosinophil Count in Patients with COPD in the UK Clinical Practice Research Datalink , 2017, COPD.

[82]  P. Burney,et al.  The association between chronic airflow obstruction and poverty in 12 sites of the multinational BOLD study , 2017, European Respiratory Journal.

[83]  Dave Singh,et al.  Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial , 2017, The Lancet.

[84]  Giacomo Grasselli,et al.  Physiologic Effects of High‐Flow Nasal Cannula in Acute Hypoxemic Respiratory Failure , 2017, American journal of respiratory and critical care medicine.

[85]  A. Torres,et al.  Discontinuing noninvasive ventilation in severe chronic obstructive pulmonary disease exacerbations: a randomised controlled trial , 2016, European Respiratory Journal.

[86]  E. Wouters,et al.  Domain-specific cognitive impairment in patients with COPD and control subjects , 2016, International journal of chronic obstructive pulmonary disease.

[87]  R. Tang,et al.  Major air pollutants and risk of COPD exacerbations: a systematic review and meta-analysis , 2016, International journal of chronic obstructive pulmonary disease.

[88]  A. Crockett,et al.  Should the diagnosis of COPD be based on a single spirometry test? , 2016, npj Primary Care Respiratory Medicine.

[89]  C. Mcevoy,et al.  Health Coaching and Chronic Obstructive Pulmonary Disease Rehospitalization. A Randomized Study. , 2016, American journal of respiratory and critical care medicine.

[90]  K. Rabe,et al.  Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial. , 2016, American journal of respiratory and critical care medicine.

[91]  F. Burgos,et al.  Different dyspnoea perception in COPD patients with frequent and infrequent exacerbations , 2016, Thorax.

[92]  Meilan K. Han,et al.  Association between Functional Small Airway Disease and FEV1 Decline in Chronic Obstructive Pulmonary Disease. , 2016, American journal of respiratory and critical care medicine.

[93]  E. Papakonstantinou,et al.  Therapy with proton‐pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD , 2016, Respirology.

[94]  D. Postma,et al.  Patterns of Growth and Decline in Lung Function in Persistent Childhood Asthma. , 2016, The New England journal of medicine.

[95]  T. Troosters,et al.  Increasing implementation and delivery of pulmonary rehabilitation: key messages from the new ATS/ERS policy statement , 2016, European Respiratory Journal.

[96]  J. Masclans,et al.  Current evidence for the effectiveness of heated and humidified high flow nasal cannula supportive therapy in adult patients with respiratory failure , 2016, Critical Care.

[97]  W. MacNee,et al.  Interventions to modify physical activity in patients with COPD: a systematic review , 2016, European Respiratory Journal.

[98]  J. Fraser,et al.  Nasal high flow oxygen therapy in patients with COPD reduces respiratory rate and tissue carbon dioxide while increasing tidal and end-expiratory lung volumes: a randomised crossover trial , 2016, Thorax.

[99]  Hakan Günen,et al.  Waterpipe tobacco smoking. , 2016, Tuberkuloz ve toraks.

[100]  A. Schols,et al.  The Prevalence of Metabolic Syndrome In Chronic Obstructive Pulmonary Disease: A Systematic Review , 2016, COPD.

[101]  D. Lomas,et al.  α1-antitrypsin deficiency , 2005, The Lancet.

[102]  Anne Holland,et al.  Pulmonary Rehabilitation Exercise Prescription in Chronic Obstructive Pulmonary Disease: Review of Selected Guidelines: AN OFFICIAL STATEMENT FROM THE AMERICAN ASSOCIATION OF CARDIOVASCULAR AND PULMONARY REHABILITATION. , 2016, Journal of cardiopulmonary rehabilitation and prevention.

[103]  Shinu Abraham,et al.  Lung-function trajectories leading to chronic obstructive pulmonary disease , 2015 .

[104]  Dave Singh,et al.  Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. , 2015, Respiratory medicine.

[105]  Meilan K. Han,et al.  Clinical and Radiologic Disease in Smokers With Normal Spirometry. , 2015, JAMA internal medicine.

[106]  Atul Malhotra,et al.  High Prevalence of Obstructive Sleep Apnea in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease. , 2015, Annals of the American Thoracic Society.

[107]  J. Wedzicha,et al.  Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. , 2015, American journal of respiratory and critical care medicine.

[108]  N. Maimon,et al.  The Association Between Hospital Readmission and Pulmonologist Follow-up Visits in Patients With COPD. , 2015, Chest.

[109]  M. Sadatsafavi,et al.  Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. , 2015, The Lancet. Respiratory medicine.

[110]  Ciro Casanova,et al.  COPD comorbidities network , 2015, European Respiratory Journal.

[111]  I. Pavord,et al.  Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. , 2015, The Lancet. Respiratory medicine.

[112]  F. Martinez,et al.  Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial , 2015, The Lancet.

[113]  G. Diette,et al.  Occupational exposures are associated with worse morbidity in patients with chronic obstructive pulmonary disease. , 2015, American journal of respiratory and critical care medicine.

[114]  J. Hallas,et al.  Gastro‐esophageal reflux disease and exacerbations in chronic obstructive pulmonary disease , 2015, Respirology.

[115]  J. Bourbeau,et al.  Clinical Relevance of Fixed Ratio vs Lower Limit of Normal of FEV1/FVC in COPD: Patient-Reported Outcomes From the CanCOLD Cohort , 2015, The Annals of Family Medicine.

[116]  Thierry Troosters,et al.  An official European Respiratory Society statement on physical activity in COPD , 2014, European Respiratory Journal.

[117]  Jun She,et al.  Chinese water-pipe smoking and the risk of COPD. , 2014, Chest.

[118]  M. Decramer,et al.  Withdrawal of inhaled glucocorticoids and exacerbations of COPD. , 2014, The New England journal of medicine.

[119]  J. E. Hansen,et al.  Counterpoint: Is an increase in FEV₁ and/or FVC ≥ 12% of control and ≥ 200 mL the best way to assess positive bronchodilator response? No. , 2014, Chest.

[120]  Stefano Nava,et al.  Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. , 2014, The Lancet. Respiratory medicine.

[121]  Edwin K Silverman,et al.  Epidemiology, genetics, and subtyping of preserved ratio impaired spirometry (PRISm) in COPDGene , 2014, Respiratory Research.

[122]  D. Mannino,et al.  Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012–2013 , 2014, International journal of chronic obstructive pulmonary disease.

[123]  R. Rodríguez-Roisín,et al.  Disease progression in young patients with COPD: rethinking the Fletcher and Peto model , 2014, European Respiratory Journal.

[124]  M. Decramer,et al.  Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study , 2013, European Respiratory Journal.

[125]  Thierry Troosters,et al.  An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. , 2013, American journal of respiratory and critical care medicine.

[126]  M. Briel,et al.  Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. , 2013, JAMA.

[127]  James D. Chalmers,et al.  Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease. , 2013, Annals of the American Thoracic Society.

[128]  B. Beghé,et al.  Exacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPD , 2013, European Respiratory Journal.

[129]  N. Roche,et al.  High-risk patients following hospitalisation for an acute exacerbation of COPD , 2013, European Respiratory Journal.

[130]  D. Mannino,et al.  Outcomes of noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease in the United States, 1998-2008. , 2012, American journal of respiratory and critical care medicine.

[131]  B. Celli,et al.  Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. , 2012, American journal of respiratory and critical care medicine.

[132]  Christopher E Brightling,et al.  Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. , 2012, American journal of respiratory and critical care medicine.

[133]  L. Edwards,et al.  Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease , 2012, Thorax.

[134]  Stefan Störk,et al.  "GOLD or lower limit of normal definition? a comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study" , 2012, Respiratory Research.

[135]  M. Cosio,et al.  Lung cancer in patients with chronic obstructive pulmonary disease-- incidence and predicting factors. , 2011, American journal of respiratory and critical care medicine.

[136]  M. Tsukino,et al.  Predictive properties of different multidimensional staging systems in patients with chronic obstructive pulmonary disease , 2011, International journal of chronic obstructive pulmonary disease.

[137]  T. To,et al.  Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study , 2011, The Lancet.

[138]  John Connett,et al.  Azithromycin for prevention of exacerbations of COPD. , 2011, The New England journal of medicine.

[139]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[140]  D. Jarvis,et al.  Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults. , 2011, American journal of respiratory and critical care medicine.

[141]  E. Akl,et al.  Effects of water-pipe smoking on lung function: a systematic review and meta-analysis. , 2011, Chest.

[142]  Patrick D Mitchell,et al.  Hypoxemia in patients with COPD: cause, effects, and disease progression , 2011, International journal of chronic obstructive pulmonary disease.

[143]  J. Vestbo,et al.  Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. , 2011, American journal of respiratory and critical care medicine.

[144]  R. Wood‐Baker,et al.  Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial , 2010, BMJ : British Medical Journal.

[145]  J. Wedzicha,et al.  Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.

[146]  Yasutaka Nakano,et al.  CT scan findings of emphysema predict mortality in COPD. , 2010, Chest.

[147]  R. Hoogenveen,et al.  Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach , 2010, European Respiratory Journal.

[148]  T. Omachi,et al.  Influence of anxiety on health outcomes in COPD , 2010, Thorax.

[149]  K. Kuwano,et al.  A Randomized, Single‐Blind Study of Lansoprazole for the Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease in Older Patients , 2009, Journal of the American Geriatrics Society.

[150]  P. Barnes,et al.  COPD as a disease of accelerated lung aging(a). , 2009, Revista portuguesa de pneumologia.

[151]  D. Mannino,et al.  The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. , 2009, American journal of respiratory and critical care medicine.

[152]  Fan Wang,et al.  The role of Scgb1a1+ Clara cells in the long-term maintenance and repair of lung airway, but not alveolar, epithelium. , 2009, Cell stem cell.

[153]  W. Vollmer,et al.  Marijuana and chronic obstructive lung disease: a population-based study , 2009, Canadian Medical Association Journal.

[154]  J. Steurer,et al.  Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. , 2009, The Cochrane database of systematic reviews.

[155]  S. Borson,et al.  Anxiety and depression in COPD: Current understanding, unanswered questions, and research needs. , 2009, Revista portuguesa de pneumologia.

[156]  D. Mannino,et al.  Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD , 2008, European Respiratory Journal.

[157]  D. Postma,et al.  Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study. , 2007, Chest.

[158]  Stefano Guerra,et al.  Poor airway function in early infancy and lung function by age 22 years: a non-selective longitudinal cohort study , 2007, The Lancet.

[159]  C. Jiang,et al.  Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study , 2007, The Lancet.

[160]  H. Gunen,et al.  The role of nebulised budesonide in the treatment of exacerbations of COPD , 2007, European Respiratory Journal.

[161]  T. Ng,et al.  Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. , 2007, Archives of internal medicine.

[162]  V. Backer,et al.  The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. , 2007, Respiratory medicine.

[163]  X. Busquets,et al.  Telomere shortening in smokers with and without COPD. , 2006, The European respiratory journal.

[164]  J. Vestbo,et al.  COPD: the dangerous underestimate of 15% , 2006, The Lancet.

[165]  J. Garcia-Aymerich,et al.  Wood smoke exposure and risk of chronic obstructive pulmonary disease , 2006, European Respiratory Journal.

[166]  Thomas Similowski,et al.  Prognostic value of the hematocrit in patients with severe COPD receiving long-term oxygen therapy. , 2005, Chest.

[167]  D. Lawlor,et al.  Association of birth weight with adult lung function: findings from the British Women’s Heart and Health Study and a meta-analysis , 2005, Thorax.

[168]  P. Calverley,et al.  Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial , 2005, Thorax.

[169]  N. Anthonisen,et al.  The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial , 2005 .

[170]  Thierry Troosters,et al.  Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. , 2005, American journal of respiratory and critical care medicine.

[171]  Mark E Kunik,et al.  Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. , 2005, Chest.

[172]  B. Rowe,et al.  Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials , 2003, BMJ : British Medical Journal.

[173]  I. Stiell,et al.  Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. , 2003, The New England journal of medicine.

[174]  Steven Piantadosi,et al.  A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. , 2003, The New England journal of medicine.

[175]  Ki Moon Bang,et al.  Association between chronic obstructive pulmonary disease and employment by industry and occupation in the US population: a study of data from the Third National Health and Nutrition Examination Survey. , 2002, American journal of epidemiology.

[176]  W. Bailey,et al.  Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution , 2023, Medical science monitor : international medical journal of experimental and clinical research.

[177]  F. Maltais,et al.  Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. , 2002, American journal of respiratory and critical care medicine.

[178]  L. Fried,et al.  Frailty in older adults: evidence for a phenotype. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.

[179]  T. Kuriyama,et al.  Effects of Hemoglobin on Pulmonary Arterial Pressure and Pulmonary Vascular Resistance in Patients with Chronic Emphysema , 2000, Respiration.

[180]  L. Davies,et al.  Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial , 1999, The Lancet.

[181]  Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation--a consensus conference report. , 1999, Chest.

[182]  I. Tager,et al.  Maternal smoking during pregnancy. Effects on lung function during the first 18 months of life. , 1995, American journal of respiratory and critical care medicine.

[183]  J. Fredberg,et al.  Relationship between maximal expiratory flows and lung volumes in growing humans. , 1988, Journal of applied physiology.

[184]  N. Anthonisen,et al.  Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. , 1987, Annals of internal medicine.

[185]  Cotes Je,et al.  LONG TERM DOMICILIARY OXYGEN THERAPY IN CHRONIC HYPOXIC COR PULMONALE COMPLICATING CHRONIC BRONCHITIS AND EMPHYSEMA Report of the Medical Research Council Working Party , 1981, The Lancet.

[186]  Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. , 1980, Annals of internal medicine.

[187]  J. Mead,et al.  Variability of maximum expiratory flow-volume curves. , 1974, Journal of applied physiology.

[188]  Report of the Medical Research Council , 1936 .